Chargement en cours...
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists
Estrogen antagonists are universally employed in the breast cancer therapy, although antagonist therapy is limited by the inevitable development of cellular resistance. The molecular mechanisms by which these agents inhibit cellular proliferation in breast cancer cells are not fully defined. Recent...
Enregistré dans:
| Publié dans: | EMBO J |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2004
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC419909/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15141164/ https://ncbi.nlm.nih.govhttps://doi.org/10.1038/sj.emboj.7600231 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|